Benzinga · Oct 7, 2026
Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12
Leerink Partners analyst Puneet Souda maintains OmniAb (NASDAQ:OABI) with a Outperform and raises the price target from $10 to $12.
OA
NASDAQ · OABI
OmniAb, Inc.
Healthcare · Biotechnology
$5.11
Down-$0.12 (-2.29%)
Updated Oct 31, 2026, 11:53 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 233M
- P/E ratio
- -3.9
- Dividend yield
- 0.00%
- 52-week range
- $1.35 – $5.43
- Volume
- 2.11M
- Avg. volume
- 564.8K
Price performance · OABI
OABI price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
OABI closed at $5.11 after 20 trading sessions, up 3.86% for the selected period.
- Last close
- $5.11
- Period change
- +3.86%
- Period low
- $4.35
- Period high
- $5.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $4.40 | $5.11 | $4.35 | $5.11 | 2.11M |
| Oct 29, 2026 | $5.35 | $5.405 | $5.14 | $5.23 | 1.68M |
| Oct 28, 2026 | $4.92 | $5.29 | $4.905 | $5.28 | 1.58M |
| Oct 27, 2026 | $4.61 | $4.98 | $4.549 | $4.96 | 1.11M |
| Oct 26, 2026 | $4.66 | $4.72 | $4.53 | $4.61 | 971.63K |
| Oct 23, 2026 | $4.70 | $4.785 | $4.515 | $4.66 | 1.28M |
| Oct 22, 2026 | $4.91 | $5.055 | $4.71 | $4.78 | 1.34M |
| Oct 21, 2026 | $4.96 | $5.1322 | $4.80 | $4.915 | 3.18M |
| Oct 20, 2026 | $4.74 | $5.105 | $4.74 | $4.96 | 1.93M |
| Oct 19, 2026 | $4.53 | $4.755 | $4.52 | $4.69 | 892.41K |
| Oct 16, 2026 | $4.73 | $4.82 | $4.505 | $4.59 | 969.61K |
| Oct 15, 2026 | $4.60 | $4.755 | $4.5306 | $4.73 | 820.69K |
| Oct 14, 2026 | $4.62 | $4.83 | $4.5301 | $4.55 | 737.81K |
| Oct 13, 2026 | $4.76 | $4.815 | $4.6203 | $4.70 | 809.48K |
| Oct 12, 2026 | $4.77 | $4.845 | $4.64 | $4.77 | 988.63K |
| Oct 9, 2026 | $4.66 | $4.915 | $4.59 | $4.79 | 1.04M |
| Oct 8, 2026 | $4.41 | $4.66 | $4.215 | $4.66 | 1.53M |
| Oct 7, 2026 | $4.35 | $4.7499 | $4.30 | $4.56 | 1.5M |
| Oct 6, 2026 | $4.85 | $5.00 | $4.215 | $4.35 | 2M |
| Oct 5, 2026 | $4.83 | $5.02 | $4.64 | $4.92 | 1.22M |
Latest OABI news
The latest Smart Investors Daily articles mentioning OABI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OABI research
Overview
Company profile and research snapshot.
Company profile
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Leerink Partners | Outperform | — |
| Oct 7, 2026 | StoneX | Buy | — |
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2025 | RBC Capital | Outperform | — |
| May 12, 2025 | Benchmark | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 7, 2026
StoneX Maintains Buy on OmniAb, Raises Price Target to $6
StoneX analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and raises the price target from $4 to $6.
ChartMill · Aug 22, 2026
OmniAb (NASDAQ:OABI) Passes Minervini Trend Template and High-Growth Momentum Screen
OmniAb (OABI) passes Minervini's trend template with strong momentum and accelerating growth, but a low setup rating suggests waiting for a pullback.
SeekingAlpha · Aug 18, 2026
OmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
OmniAb (OABI) analysis: platform scaling via Eli Lilly partnership, milestone-rich revenue outlook, 2026 cash guidance, valuation and catalystsâread now.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
